OECD Pharmaceutical Consumption And Sales By ATC Codes

$179 / year

This dataset contains internationally comparable indicators regarding the pharmaceutical consumption and sales, including OTC (over-the-counter) drugs for country members of OECD (The Organization for Economic Co-operation and Development) and for countries in accession negotiations with OECD. The indicators values cover the period 1980-2016.

Complexity

The OECD (The Organization for Economic Co-operation and Development) mission is to promote policies that will improve the economic and social well-being of people around the world. OECD’s work is based on continued monitoring of events in member countries as well as outside OECD area, and includes regular projections of short and medium-term economic developments. The OECD Secretariat collects and analyses data, after which committees discuss policy regarding this information, the Council makes decisions, and then governments implement recommendations. The OECD Health Datasets offers the most comprehensive source of comparable statistics on health and health systems across OECD countries. It is an essential tool to carry out comparative analyses and draw lessons from international comparisons of diverse health systems.

The Anatomic Therapeutic Chemical Classification system divides drugs into different groups according to the organ system on which they act and/or therapeutic, pharmacological and chemical characteristics. The main principles for the classification of medicinal substances according to the ATC is presented in the publication “Guidelines for ATC classification and DDD assignment”, WHO Collaborating Centre for Drug Statistics Methodology, Oslo. The publication “ATC Index with DDDs” lists all assigned ATC codes and DDD (Defined Daily Dose) values. Both these publications are updated annually. The ATC codes used are based on the 2017 version of the ATC Index. For pharmaceutical consumption indicator by DDD the following sources were used data on Antibacterials for systemic use (J01) for the period 1997-2015:

– ESAC-Net Database for the years indicated: France (1997-2015), Greece (1997-2015), Ireland (1998-2015), Latvia (2002-2011), Luxembourg (1997-2008), Poland (1998-2015), Slovenia (1997-2011), Spain (1997-2011), and the United Kingdom (1997-2011)
– Directly provided by countries for: Austria, Belgium, the Czech Republic, Denmark, Estonia, Finland, Germany, Greece (1990-1996), Hungary, Iceland, Israel, Italy, Latvia (2012 onwards), Luxembourg (2009 onwards), the Netherlands, Norway, Portugal, the Slovak Republic, Slovenia (2012 onwards), Spain (2012 onwards), Sweden, the United Kingdom (2012 onwards), and Turkey

Pharmaceutical sales refer to the sales of pharmaceutical products on the domestic market, in total and by selected Anatomic Therapeutic Chemical (ATC) groups, based on retail prices (which means the final price paid by the customer). There are at least three possible sources of under-reporting of drug sales in different countries:

– Sales data may only cover those drugs that are reimbursed by public insurance schemes
– Sales data may be based on ex-factory or wholesale prices rather than retail prices and
– Sales data may exclude drug consumption in hospitals

Data for the following countries under-estimate pharmaceutical sales reported because of one of these limitations: Australia, France, Germany, Japan, Luxembourg, the Netherlands, the Slovak Republic and Spain. Depending on the allocation of pharmaceutical products with more than one use, differences in reporting of specific drugs may occur across countries, thereby affecting the relative size of specific ATC groups.

A generic drug is a pharmaceutical product which has the same qualitative and quantitative composition in active substances and the same pharmaceutical form as the reference medicinal product, and whose bio-equivalence with the reference medicinal product has been demonstrated by appropriate bio-availability studies. Generics can be classified in branded generics (generics with a specific trade name) and unbranded generics (which use the international non-proprietary name and the name of the company). Data for generic drugs are collected as a share expressed in value or volume. Values can for instance be the turnover of pharmaceutical companies, the amount paid for pharmaceuticals by third-party payers, or the amount paid all payers (third-party and consumers). Market value are most often at ex-factory prices, while amounts paid by third-party payers (and consumers) are in general at retails prices. Volumes can be expressed in DDDs or as a number of packages/boxes or standard units.

The reimbursement market is the sub-market in which a third party payer reimburses medicines.

Breaks in the time-related continuity of data on which the calculated indicators values are based are specified in the content of dataset. There are also specified the cases were the methodology used for data collection was different or if the values are estimated.

Date Created

2017-11-10

Last Modified

2017-11-10

Version

2017-11-10

Update Frequency

Irregular

Temporal Coverage

1980-2016

Spatial Coverage

OECD Members and Partners Countries

Source

John Snow Labs; The Organization for Economic Co-operation and Development;

Source License URL

Source License Requirements

N/A

Source Citation

N/A

Keywords

OECD Health Care Indicators, OECD Pharmaceutical Market, Pharmaceutical Consumption, Consumption By Drugs Types, Pharmaceutical Sales, ATC Classification, Sales In US Dollars, Generic Market Share, Defined Daily Dose

Other Titles

OECD Countries Pharmaceutical Market Indicators, Sales And Consumption Of Drugs By Type In OECD Countries

NameDescriptionTypeConstraints
YearThe year corresponding to the specified pharmaceutical market indicator value for a countrydaterequired : 1
CountryThe name of the country member of OECD or in accession negotiations with OECDstringrequired : 1
Country_AbbreviationThe abbreviated name of the country member of OECD or in accession negotiations with OECDstringrequired : 1
Country_StatusSpecifies whether the country is member of OECD or has an accession agreement with OECDstringenum : Array required : 1
Indicator_CategorySpecifies a group of indicators related to the pharmaceutical marketstringenum : Array required : 1
Measurement_MethodDescribes how the indicator is measuredstringrequired : 1
Drugs_Type_ATC2017The type of drugs according to the 2017 revision of Anatomic Therapeutic Chemical Classificationstring-
Drugs_TypeATC2017_CodeThe corresponding ATC code according to the 2017 revision of Anatomic Therapeutic Chemical Classificationstring-
Pharmaceutical_Market_Indicator_ValueThe calculated value of the indicator for the specified year and countrynumberlevel : Ratio
Additional_NotesAdditional information related to the indicator value or measurementstring-
Is_Data_Include_Drugs_Dispensed_In_HospitalSpecifies if the indicator is calculated using data for drugs dispensed in hospitalboolean-
Is_Data_Include_Non_Reimbursed_DrugsSpecifies if the indicator is calculated using data for non-reimbursed drugsboolean-
Is_Data_IncludeOTC_DrugsSpecifies if the indicator is calculated using data for over-the-counter drugsboolean-
Is_Vat_IncludedSpecifies if the indicator is calculated using monetary data which include VATboolean-
YearCountryCountry AbbreviationCountry StatusIndicator CategoryMeasurement MethodDrugs Type ATC2017Drugs TypeATC2017 CodePharmaceutical Market Indicator ValueAdditional NotesIs Data Include Drugs Dispensed In HospitalIs Data Include Non Reimbursed DrugsIs Data IncludeOTC DrugsIs Vat Included
1980IcelandISLOECD memberPharmaceutical spendingAmount of millions USD (at exchange rate) adjusted with purchasing power parityAlimentary tract and metabolismA3.1TrueTrueFalseTrue
1980JapanJPNOECD memberPharmaceutical spendingAmount of millions USD (at exchange rate) adjusted with purchasing power parityAlimentary tract and metabolismA994.2FalseTrueTrueTrue
1980NetherlandsNLDOECD memberPharmaceutical spendingAmount of millions USD (at exchange rate) adjusted with purchasing power parityAlimentary tract and metabolismA64.1FalseFalseFalseTrue
1980IcelandISLOECD memberPharmaceutical spendingAmount of millions USD (at exchange rate) adjusted with purchasing power parityBlood and blood forming organsB0.4TrueTrueFalseTrue
1980JapanJPNOECD memberPharmaceutical spendingAmount of millions USD (at exchange rate) adjusted with purchasing power parityBlood and blood forming organsB695.4FalseTrueTrueTrue
1980NetherlandsNLDOECD memberPharmaceutical spendingAmount of millions USD (at exchange rate) adjusted with purchasing power parityBlood and blood forming organsB10.2FalseFalseFalseTrue
1980IcelandISLOECD memberPharmaceutical spendingAmount of millions USD (at exchange rate) adjusted with purchasing power parityCardiovascular systemC4.1TrueTrueFalseTrue
1980JapanJPNOECD memberPharmaceutical spendingAmount of millions USD (at exchange rate) adjusted with purchasing power parityCardiovascular systemC1655.6FalseTrueTrueTrue
1980NetherlandsNLDOECD memberPharmaceutical spendingAmount of millions USD (at exchange rate) adjusted with purchasing power parityCardiovascular systemC103.4FalseFalseFalseTrue
1980IcelandISLOECD memberPharmaceutical spendingAmount of millions USD (at exchange rate) adjusted with purchasing power parityGenito urinary system and sex hormonesG1.1TrueTrueFalseTrue